Benzinga | Aug 5, 2021 08:18AM EDT

Ensysce Biosciences Highlights Notice Of Allowance From US Patent & Trademark Office For 'Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof'

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.

The invention comprises a method for controlled release of amphetamine to a patient using the Trypsin-Activated Abuse Protection (TAAP) platform of Ensysce, which has been applied previously to the company's opioid products, to reduce abuse. The allowed claims also cover administering these amphetamine prodrugs with a GI enzyme inhibitor, in accordance with Ensysce's Multi-Pill Abuse Resistance (MPAR(tm)) platform, providing overdose protection to this class of agents.

"We are pleased to be growing our patent portfolio," said Ensysce CEO Dr. Lynn Kirkpatrick. "This issuance provides the company with another possibility to build our pipeline of products for ADHD indications. We believe that our TAAP and MPAR(tm) platforms applied to this category of prescription drugs are unique in the industry."